Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

Now Viewing

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asked Abraham about the role of provider acceptance and confidence in biosimilars in driving adoption for inflammatory conditions.

Abraham said if a payer requires switching to a biosimilar, providers must comply regardless of confidence. However, provider knowledge of the biosimilar’s efficacy, safety, expected effects of switching, and so on allows confident counseling of patients concerned about changes in their medication for chronic disease. An informed provider can explain details to patients, reducing nocebo effects from anxiety about switching. Provider knowledge and confidence in biosimilars significantly helps adoption from the provider and patient standpoint.

Haumschild agreed that provider understanding of data enables confident prescribing and trust from patients, which has been crucial for biosimilar adoption. This transition of acceptance and confidence will be vital as inflammatory disease options expand.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.